Ahead of presentations at the 6th Annual DDR Inhibitors Summit in Boston this week, Oren Gilad, Ph.D., president and CEO of Aprea, and Eric Brown, Ph.D., Scientific Consultant to Aprea, member of the company’s Scientific Advisory Board, and Associate Professor of Cancer Biology at the University of Pennsylvania, took time out to speak with BioBuzz about the company and the significance of new target and biomarker identification in oncology research.